{"nct_id":"NCT05104866","title":"A Phase-3, Open-Label, Randomized Study of Dato-DXd Versus Investigator's Choice of Chemotherapy (ICC) in Participants With Inoperable or Metastatic HR-Positive, HER2-Negative Breast Cancer Who Have Been Treated With One or Two Prior Lines of Systemic Chemotherapy (TROPION-Breast01)","status":"ACTIVE_NOT_RECRUITING","status_verified_date":"2025-03","start_date":"2021-10-18","start_date_type":"ACTUAL","primary_completion_date":"2024-07-24","primary_completion_date_type":"ACTUAL","completion_date":"2025-12-31","completion_date_type":"ESTIMATED","phases":["PHASE3"],"tickers":["AZN"]}